Robert P Jones1, Norihiro Kokudo2, Gunnar Folprecht3, Yoshihiro Mise2, Michiaki Unno4, Hassan Z Malik5, Stephen W Fenwick5, Graeme J Poston5. 1. School of Cancer Studies, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; North Western Hepatobiliary Unit, Aintree University Hospital, Liverpool, United Kingdom. 2. Department of Surgery, University of Tokyo, Tokyo, Japan. 3. University Hospital Carl Gustav Carus, University Cancer Center, Dresden, Germany. 4. Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. 5. North Western Hepatobiliary Unit, Aintree University Hospital, Liverpool, United Kingdom.
Abstract
BACKGROUND: Over 50% of patients with colorectal cancer will develop liver metastases. Only a minority of patients present with technically resectable disease. Around 40% of those undergoing surgical resection are alive five years after their diagnosis compared with less than 1% for those with disseminated disease treated with systemic chemotherapy. Surgical resection remains the only possibility for long-term survival for these patients and great efforts have been made to increase the rates of resection whilst improving long-term outcomes. SUMMARY: This review considers current technical and oncological criteria for resection, as well as targeted approaches to stratify underlying tumor biology in order to better predict long-term benefit. The role of neoadjuvant and perioperative systemic chemotherapy is critically reviewed, with suggestions for patient stratification in order to identify those who are likely to derive the greatest benefit. The key role of multidisciplinary assessment and decision making for these complex patients is also discussed. KEY MESSAGES: Surgery remains the optimal treatment for colorectal liver metastases (CRLM). Despite the curative intent of surgical resection, the majority of patients develop recurrence. Surgical strategies should therefore be adopted to maximize the potential for repeat resections in the event of recurrence. Although a number of preoperative prognostic markers have been identified, none are absolute contraindications to resection. In order to reduce postoperative recurrence, neo-adjuvant chemotherapy is now the standard of care in a number of countries. The evidence base for this approach is contentious, and the potential benefit of such a strategy is likely to be greatest in patients with high oncological risk disease. Multidisciplinary care is essential to ensure the optimal management of these complex patients. In addition, all patients with CRLM should be discussed with specialist hepatobiliary surgeons.
BACKGROUND: Over 50% of patients with colorectal cancer will develop liver metastases. Only a minority of patients present with technically resectable disease. Around 40% of those undergoing surgical resection are alive five years after their diagnosis compared with less than 1% for those with disseminated disease treated with systemic chemotherapy. Surgical resection remains the only possibility for long-term survival for these patients and great efforts have been made to increase the rates of resection whilst improving long-term outcomes. SUMMARY: This review considers current technical and oncological criteria for resection, as well as targeted approaches to stratify underlying tumor biology in order to better predict long-term benefit. The role of neoadjuvant and perioperative systemic chemotherapy is critically reviewed, with suggestions for patient stratification in order to identify those who are likely to derive the greatest benefit. The key role of multidisciplinary assessment and decision making for these complex patients is also discussed. KEY MESSAGES: Surgery remains the optimal treatment for colorectal liver metastases (CRLM). Despite the curative intent of surgical resection, the majority of patients develop recurrence. Surgical strategies should therefore be adopted to maximize the potential for repeat resections in the event of recurrence. Although a number of preoperative prognostic markers have been identified, none are absolute contraindications to resection. In order to reduce postoperative recurrence, neo-adjuvant chemotherapy is now the standard of care in a number of countries. The evidence base for this approach is contentious, and the potential benefit of such a strategy is likely to be greatest in patients with high oncological risk disease. Multidisciplinary care is essential to ensure the optimal management of these complex patients. In addition, all patients with CRLM should be discussed with specialist hepatobiliary surgeons.
Authors: T Ruers; C Punt; F Van Coevorden; J P E N Pierie; I Borel-Rinkes; J A Ledermann; G Poston; W Bechstein; M A Lentz; M Mauer; E Van Cutsem; M P Lutz; B Nordlinger Journal: Ann Oncol Date: 2012-03-19 Impact factor: 32.976
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: Graeme J Poston; René Adam; Steven Alberts; Steven Curley; Juan Figueras; Daniel Haller; Francis Kunstlinger; Gilles Mentha; Bernard Nordlinger; Yehuda Patt; John Primrose; Mark Roh; Philippe Rougier; Theo Ruers; Hans Joachim Schmoll; Carlos Valls; Nick Jean-Nicolas Vauthey; Marleen Cornelis; James P Kahan Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Junichi Shindoh; Evelyne M Loyer; Scott Kopetz; Piyaporn Boonsirikamchai; Dipen M Maru; Yun Shin Chun; Giuseppe Zimmitti; Steven A Curley; Chusilp Charnsangavej; Thomas A Aloia; Jean-Nicolas Vauthey Journal: J Clin Oncol Date: 2012-11-13 Impact factor: 44.544
Authors: R P Jones; S Stättner; D F J Dunne; E O'Grady; A Smethurst; M Terlizzo; H Z Malik; S W Fenwick; G J Poston Journal: Eur J Surg Oncol Date: 2013-08-06 Impact factor: 4.424
Authors: R P Jones; J-N Vauthey; R Adam; M Rees; D Berry; R Jackson; N Grimes; S W Fenwick; G J Poston; H Z Malik Journal: Br J Surg Date: 2012-09 Impact factor: 6.939
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Date: 2008-03-22 Impact factor: 79.321
Authors: Kim Sivesgaard; Lars P Larsen; Michael Sørensen; Stine Kramer; Sven Schlander; Nerijus Amanavicius; Arindam Bharadwaz; Dennis Tønner Nielsen; Frank Viborg Mortensen; Erik Morre Pedersen Journal: Eur Radiol Date: 2018-05-07 Impact factor: 5.315
Authors: Babs G Sibinga Mulder; Henricus Jm Handgraaf; Danielle J Vugts; Claudia Sewing; Albert D Windhorst; Marieke Stammes; Lioe-Fee de Geus-Oei; Mark W Bordo; J Sven D Mieog; Cornelis Jh van de Velde; John V Frangioni; Alexander L Vahrmeijer Journal: Am J Nucl Med Mol Imaging Date: 2018-10-20
Authors: K Aitken; J Good; M Hawkins; D Grose; S Mukherjee; M Harrison; G Radhakrishna Journal: Clin Oncol (R Coll Radiol) Date: 2020-05-01 Impact factor: 4.126
Authors: Sven H Loosen; Frank Tacke; Marcel Binnebosel; Catherine Leyh; Mihael Vucur; Florian Heitkamp; Wenzel Schoening; Tom F Ulmer; Patrick H Alizai; Christian Trautwein; Alexander Koch; Thomas Longerich; Christoph Roderburg; Ulf P Neumann; Tom Luedde Journal: Oncotarget Date: 2018-06-05